… for the treatment of severe COVID-19. The aim of this systematic review was to describe
the rationale for the use of tocilizumab for the treatment of COVID-19 and to summarize the …

… rates for SARS and MERS, COVID-19 has led to more deaths … , 6 a characteristic feature of
COVID-19 is that a proportion of … been described in patients with COVID-19, and this review …

… COVID-19 caused by SARS-CoV-2 is associated with an … The manifestations of severe
COVID-19 such as the ARDS, … MERS-CoV infection linking severe COVID-19 disease directly with …

… Approximately 15% of coronavirus disease‐2019 (COVID‐19… ARDS, the leading cause
of death in COVID‐19 patients, … Besides affecting the respiratory system, COVID‐19 affects …

… coronavirus (MERS-CoV) prompted the identification of compounds that could theoretically
be active against the emerging coronavirus … considerations in COVID-19 patients in order to …

… In January, a highly contagious novel coronavirus (now … safe and effective treatments for
COVID-19 patients because, … sector for the use of MSC therapies in COVID-19 patients. MSCs …

… or late stage molecules for COVID-19, parallel to the … adoption of azithromycin in routine
COVID-19 care, further fuelled … we comprehensively review the rationale of its use against SARS-…

… in COVID-19 patients with the rationale that it may help clear the SARS-CoV-2 earlier in the
disease course. However, in the later phase of COVID-19 … the onset of COVID-19 pneumonia …

… Despite the recent announcement of promising drug candidates to treat COVID-19, there
is … for the severity of disease seen in COVID-19 patients. In support of this hypothesis, pilot …

… rationale and design of an international, multicentre, observational registry of patients with
COVID-19 … To date, the characterisation of patients admitted to ICUs with COVID-19 has been …